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Abstract
Cancer associated fibroblasts (CAFs) comprise the majority of the tumor bulk of pancreatic 
adenocarcinomas (PDACs). Current efforts to eradicate these tumors focus predominantly on 
targeting the proliferation of rapidly growing cancer epithelial cells. We know that this is largely 
ineffective with resistance arising in most tumors following exposure to chemotherapy. Despite the 
long-standing recognition of the prominence of CAFs in PDAC, the effect of chemotherapy on 
CAFs and how they may contribute to drug resistance in neighboring cancer cells is not well 
characterized. Here we show that CAFs exposed to chemotherapy play an active role in regulating 
the survival and proliferation of cancer cells. We found that CAFs are intrinsically resistant to 
gemcitabine, the chemotherapeutic standard of care for PDAC. Further, CAFs exposed to 
gemcitabine significantly increase the release of extracellular vesicles called exosomes. These 
exosomes increased chemoresistance-inducing factor, Snail, in recipient epithelial cells and 
promote proliferation and drug resistance. Finally, treatment of gemcitabine-exposed CAFs with 
an inhibitor of exosome release, GW4869, significantly reduces survival in co-cultured epithelial 
cells, signifying an important role of CAF exosomes in chemotherapeutic drug resistance. 
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Collectively, these findings show the potential for exosome inhibitors as treatment options 
alongside chemotherapy for overcoming PDAC chemoresistance.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of less than 7% 
(1). PDAC is currently the fourth leading cause of cancer-related deaths in the United States 
and is predicted to become the second leading cause of cancer-related deaths by 2030 (2). 
The poor prognosis of the disease is associated with late detection, aggressive tumor biology, 
and poor response to available therapies. Gemcitabine, a nucleoside analog, is the standard 
chemotherapeutic agent for adjuvant therapy of resectable PDAC and a commonly used 
agent in other treatment settings, including neoadjuvant treatment of borderline resectable 
PDAC and palliative treatment of metastatic PDAC. Despite gemcitabine being one of the 
most commonly used, single chemotherapeutic agents in pancreatic cancer, response rates 
are poor. The vast majority of patients (74%) receiving adjuvant gemcitabine eventually 
show tumor recurrence (3). This dismal prognosis shows an urgent need for greater 
understanding of the complete biology of PDAC in order to develop effective therapeutic 
strategies.
Current therapies focus predominantly on targeting the proliferation of the rapidly growing 
epithelial cancer cells. However, many cells types, including supporting cells called 
fibroblasts, contribute to the microenvironment surrounding cancer cells. Remarkably, the 
majority of the tumor bulk of PDACs consists of fibroblasts (4). Fibroblasts may inhibit or 
foster tumor development (5). They were previously believed to serve merely a passive role 
in PDAC drug resistance, impeding drug delivery by physically blocking cytotoxic 
chemotherapeutics from reaching their target epithelial cells (6, 7). This led to the 
development of fibroblast-depleting therapies. Unfortunately, these therapies showed either 
very small increases in survival (8) or more aggressive tumors (9). These results show a need 
to better understand how fibroblasts react to chemotherapy and how they may contribute to 
drug resistance, instead of merely depleting fibroblasts, in order to devise effective treatment 
strategies.
Recent studies have shown that exosomes, secreted membrane vesicles that range in size 
from 30–100 nm in diameter (10, 11), released from fibroblasts have been found to increase 
invasive behavior (12) and therapy resistance pathways (13) in breast cancer cells. Exosomes 
contain mRNA, DNA, proteins, and are enriched with miRNA (14). Several studies have 
shown that exosomal-derived miRNAs promote metastases (15) and enhance endothelial cell 
migration (16). Yet no studies have examined the effect(s) of exosomes derived from 
fibroblasts exposed to chemotherapy.
In this study, we show that cancer-associated fibroblasts (CAFs) are innately chemoresistant 
and play an active role in regulating the chemoresistance of cancer cells. CAFs exposed to 
Richards et al. Page 2
Oncogene. Author manuscript; available in PMC 2017 March 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
gemcitabine dramatically increase the release of exosomes that increased cell proliferation 
and survival in recipient epithelial cancer cells. Mechanistically, we demonstrated that the 
expression of Snail (SNAI1) as well as the Snail target, microRNA-146a, was increased in 
the exosomes of gemcitabine-treated CAFs. Furthermore, suppressing CAF exosome release 
in vitro reduced Snail expression in co-cultured epithelial cancer cells and reduced survival 
of drug-resistant cancer cells, suggesting that blocking exosome communication may be a 
promising new therapeutic strategy for patients receiving gemcitabine-based treatment 
regimens.
RESULTS
Pancreatic Fibroblasts are Innately Chemoresistant
We first compared the innate drug resistance of cancer-associated fibroblast (CAF) cell lines 
created from patient-derived tumor samples with that of epithelial cancer cell lines. Patient-
derived fibroblasts were grown out of tumor samples obtained from patients who had 
undergone surgical resection. The CAFs displayed an elongated, mesenchymal morphology, 
and stained positively for fibroblast markers vimentin and α-SMA (17) (Figure 1a). 
Sequencing revealed no KRAS mutation, indicating that these CAF cell lines were truly of 
fibroblast origin (Supplementary Figure S1). CAFs and normal fibroblasts had greater 
survival rates than chemoresistant epithelial cells (PANC1) and chemosensitive epithelial 
cells (L3.6) when treated with the same dosage of the chemotherapeutic agent, gemcitabine 
(GEM) (Figure 1b). Having shown that CAFs are resistant to GEM, we next assessed if the 
increased survival of CAFs exposed to GEM could be a result of CAFs undergoing 
senescence and not incorporating the drug. Therefore, we analyzed cell proliferation of 
GEM-treated CAFs and epithelial cells. The most chemoresistant CAF cell line, CAF1, also 
retained the most proliferation during GEM treatment, while the second leading resistant 
CAF cell line, CAF2, showed dramatically decreased proliferation (Figure 1c). To further 
elucidate the role of proliferation on chemoresistance, we compared the survival rate of 
CAFs and epithelial cells with similar proliferation rates (CAF2 and PANC1 cell lines, 
respectively). Although CAF2 and PANC1 cells both demonstrate a relatively low 
proliferation rate following exposure to GEM, CAF2 cells still showed more than a 2-fold 
higher cell survival rate compared to PANC1 cells following GEM treatment (Figure 1d). 
Taken together, these data demonstrate that fibroblasts have an innate resistance to GEM 
instead of a growth-dependent resistance mechanism.
Pancreatic CAF-Conditioned Media Increases Proliferation and Survival of Epithelial 
Cancer Cells
Considering the important role of cell extrinsic factors on cell growth and survival, we next 
assessed whether factors secreted by the innately chemoresistant fibroblasts could affect 
proliferation and survival of epithelial cancer cells. We first determined the effect CAF-
conditioned media had on the proliferation of chemosensitive L3.6 cells. An equivalent 
number of L3.6 or CAF cells were plated and incubated in DMEM for 24 hours. 
Conditioned cell media from either the L3.6 or the CAF cells was then transferred onto 
recipient L3.6 cells each day for six days. CAF-conditioned media increased proliferation of 
L3.6 cells by more than 50% compared to L3.6-conditioned media (Figure 2a–b). Having 
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demonstrated that media from GEM-resistant CAF cells could increase the proliferation of 
GEM-sensitive L3.6 cells, we next assessed if this effect was CAF specific or if GEM-
resistant epithelial cancer cells could also elicit this change in proliferation. We observed 
that conditioned media from the chemoresistant PANC1 epithelial cancer cell line did not 
elicit a significant increase in proliferation (Supplementary Figure S2). Next, we determined 
if CAF-conditioned media also affected the chemoresistance of epithelial cells. L3.6 cells 
were grown in either L3.6 or CAF cell-conditioned media for 6 days then treated with 
100nM gemcitabine for 3 days, and cell survival was assessed. We observed that L3.6 cells 
grown in CAF-conditioned media and subsequently treated with gemcitabine showed a 
significant increase in cell survival compared to L3.6 cells grown in L3.6 conditioned media 
(Figure 2c–d). Taken together, these data show that CAF-secreted factors affect proliferation 
and drug resistance of epithelial cancer cells.
Gemcitabine Increases CAF Exosome Secretion
Exosomes are cell-derived vesicles that can serve as important intercellular regulators of 
many oncogenic properties (18). Given that CAF-conditioned media regulates proliferation 
and drug resistance of epithelial cancer cells, we asked whether CAF-derived exosomes 
might contribute to this effect. First, exosomes were purified from the conditioned media of 
CAF cells and their size and structure was confirmed using transmission electron 
microscopy as well as particle size analysis. Particles ranged from ~20nm to ~80nm in 
diameter, indicative of exosomes (19), and immunoblotting of purified exosomes revealed 
expression of CD81, a known exosome marker (20) (Figure 3a; Supplementary Figure S3). 
We next assessed the effect gemcitabine treatment had on exosome release in CAFs. 
Samples obtained from the media of gemcitabine-treated CAFs displayed a more intense 
CD81 band by immunoblotting than untreated CAFs, suggesting a greater number of 
exosomes were present in the media of GEM treated CAFs (Figure 3a). To investigate this 
further, CAFs were transduced with a lentiviral vector that allowed the visualization of 
exosomes by labeling CD63, a known exosome marker (20), with Green Fluorescent Protein 
(GFP). Upon gemcitabine treatment, CAFs displayed increased levels of GFP expression 
(Figure 3b–c), suggesting that GEM treatment caused augmented levels of CD63 expression, 
potentially from increased exosome production. To confirm this possibility, conditioned 
media was collected from untreated and gemcitabine treated CAF cell lines and epithelial 
pancreatic cancer cell lines, and the number of exosomes was quantified. While all cell lines 
increased exosome secretion upon gemcitabine treatment, pancreatic CAFs and wild type 
fibroblasts displayed the largest increase in exosome release, significantly increasing the 
amount of exosomes found in the media more than 7-fold following gemcitabine treatment 
(Figure 3d). Having shown that gemcitabine caused increased exosome release from CAF 
cell lines, we next assessed if this effect was observed in CAFs treated with nab-paclitaxel, 
an agent that is now commonly used along with gemcitabine (8). CAFs treated with nab-
paclitaxel also showed a significant increase in released exosomes compared to untreated 
controls, but to a lesser extent than the release observed following gemcitabine treatment 
(Supplementary Figure S4). These data reveal that CAFs increase exosome secretion during 
chemotherapy treatment.
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CAF Exosomes Increase Proliferation and Survival of Cancer Epithelial Cells
To determine if these exosomes released by gemcitabine-treated CAFs could affect epithelial 
cell behavior we first tested if epithelial cells could naturally take up CAF-derived 
exosomes. We collected media from CAFs transduced with a GFP-CD63 lentivirus (GFP-
CD63-CAFs). This media was incubated on L3.6 cells for 48 hours, and the cells were 
imaged. We observed that L3.6 cells, as well as several other PDAC cell lines, cultured with 
media from GFP-CD63-CAFs were positive for GFP-expression, indicative of exosome 
uptake (21) (Figure 4a; Supplementary Figure S5).
Having confirmed that epithelial cells could uptake CAF-derived exosomes, we next studied 
the effect gemcitabine-treated CAF exosomes have on cell behavior in recipient cells. 
Equivalent numbers of CAFs were plated in exosome free media and then treated with PBS 
or 1µM gemcitabine for the same duration of time. Exosomes were then isolated from the 
CAF cell conditioned media and added to the epithelial cancer cell lines. Exosomes derived 
from gemcitabine-treated (GT) CAFs significantly increased epithelial cell proliferation and 
chemoresistance more than exosomes derived from untreated CAFs (Supplementary Figure 
S6). Therefore, we further assessed the role of GT-CAF-derived exosomes in regulating 
epithelial cell proliferation and chemoresistance in both chemosensitive and chemoresistant 
PDAC cell lines. GT-CAF exosomes increased both proliferation (Figure 4b) and survival 
(Figure 4c) of chemosensitive epithelial L3.6 cells. In contrast, exosomes from GT-
chemoresistant-epithelial-PANC1 cell exosomes did not elicit the same response (Figure 4b–
c). Further, GT-CAF exosomes also increased proliferation and survival of chemoresistant 
PANC1 and AsPC1 cells (Figure 4d–e). Thus, these data indicate that exosomes released by 
gemcitabine-treated CAFs are capable of increasing proliferation and survival in recipient 
epithelial cells.
Pancreatic CAFs Alter Snail and miR-146a Expression during Gemcitabine Treatment
Prompted by these results, we next sought to investigate the molecular mechanism 
responsible for the ability of exosomes derived from gemcitabine-treated CAFs to increase 
proliferation and survival in recipient epithelial cells. To elucidate this, we first sought to 
determine how pancreatic fibroblasts are innately chemoresistant. CAFs were treated with 
gemcitabine, and the expression levels of miRNAs were analyzed via miRNA-Seq. We 
observed that fibroblasts showed a marked increase in microRNA-146a (miR-146a) 
expression following gemcitabine treatment (Supplementary Table S1). To further 
investigate this, we utilized RT-PCR to determine the expression of miR-146a in CAFs 
treated with gemcitabine compared to untreated CAFs. Gemcitabine-treated CAFs 
demonstrated significantly higher expression of miR-146a compared to untreated CAFs 
(Figure 5a). miR-146a is directly regulated by the promoter binding transcription factor, 
Snail, which promotes chemoresistance, EMT, and metastasis (22). Therefore, we 
investigated if gemcitabine treatment of CAFs caused increased expression of Snail. Indeed, 
gemcitabine exposure also increased Snail expression in CAFs (Figure 5a). Furthermore, 
knockdown of Snail expression using siRNA caused downregulation of miR-146a 
expression in CAFs (Figure 5b). These data establish a gemcitabine-induced upregulation of 
the Snail pathway in CAFs.
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Gemcitabine Increases the Secretion of Both miR-146a And Snail through Pancreatic CAF 
Exosomes
Since GEM upregulates Snail and miR-146a expression in PDAC CAFs and GT-CAF 
exosomes increase proliferation and survival in epithelial cells, we next investigated if Snail 
and miR-146a could be delivered to cells through GT-CAF exosomes. Since exosomes 
contain both microRNAs and mRNA (14) we first tested if both miR-146a and Snail mRNA 
were increased in GT-CAF-derived exosomes. We observed that gemcitabine treatment 
increased the amount of both miR-146a and Snail mRNA in CAF-derived exosomes (Figure 
5c). Furthermore, the addition of GT-CAF exosomes to epithelial cell media also increased 
the levels of Snail mRNA (Figure 5d) and miR-146a (Figure 5e) within recipient 
chemosensitive and chemoresistant epithelial cells. Thus, our data reveal that exosomes 
produced by gemcitabine-treated CAFs augment Snail and miR-146a levels in epithelial 
cells.
Blocking CAF Exosome Secretion Reduces PDAC Cell Survival
Having shown that chemotherapy treatment of CAFs causes the increased secretion of 
chemoresistance-inducing exosomes, and increased cell survival, we next assessed whether 
blocking exosome secretion would sensitize PDAC cells to gemcitabine. First, we assessed 
whether physically removing exosomes from CAF-condition media would affect its ability 
to increase cell survival in epithelial cells following exposure to gemcitabine. AsPC1 cells 
were cultured in CAF-conditioned and exosome-depleted CAF-conditioned media. 
Exosome-depleted conditioned media was spun down at 120,000× g to pellet exosomes 
without depleting the media of proteins. We observed that culturing AsPC1 cells in CAF-
conditioned media, compared to AsPC1-conditioned media, led to greater survival rate 
during GEM treatment; however, this survival rate was significantly reduced when exosomes 
in CAF-conditioned media were removed (Figure 6a). Having shown that physically 
removing exosomes from CAF-conditioned media reduced its ability to increase 
chemoresistance, we next sought to determine if a compound that pharmacologically blocks 
exosome secretion would elicit the same effect. Therefore, the drug, GW4869, which blocks 
exosome secretion (23), was utilized to block CAF exosome release in vitro and determine 
its impact on epithelial cell survival. First, we determined if GW4869 could successfully 
block exosome secretion in CAFs. We found that GW4869 decreased CAF exosome 
secretion by ~70% in vitro in both untreated and gemcitabine treated CAFs (Figure 6b). 
Furthermore, we found that depletion of exosomes from CAF-conditioned media, using 
GW4869 treatment or centrifugation, significantly reduced expression of both Snail (Figure 
6c) and miR-146a (Figure 6d) in recipient epithelial cells receiving the CAF-conditioned 
media. Next, we utilized co-culture studies to assess if GW4869 treatment of CAFs would 
affect cell survival in recipient epithelial cells. CAFs were plated on permeable inserts above 
chemoresistant or chemosensitive epithelial cells. While cells co-cultured with CAFs 
showed a significantly increased survival rate following exposure to gemcitabine, blocking 
CAF exosome secretion using GW4869 treatment significantly reduced this survival benefit 
in multiple cell lines (Figure 6c; Supplementary Figure S7).
Lastly, we utilized a subcutaneous model to determine the effect of blocking exosome 
secretion with GW4869 on tumor growth in vivo. CAFs and AsPC1 cells were 
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subcutaneously implanted into NOD/SCID mice and treated with PBS (control), 
gemcitabine, or GW4869 alongside gemcitabine (100mg/kg body weight) twice weekly for 
two weeks. Tumors of control mice and mice treated with gemcitabine steadily increased in 
size over time, while tumors of mice given combination therapy (GW4869 and gemcitabine) 
remained relatively the same size, displaying significantly reduced growth rate 10 days after 
treatment compared to control (Supplementary Figure S8). Taken together, these data 
suggest that GT-CAF derived exosomes are a key regulator of PDAC cell chemoresistance; 
however, blocking exosome release may circumvent increased chemoresistance caused by 
exosome-mediated signaling (Figure 7).
DISCUSSION
In this study, we show that exosomes from CAFs exposed to chemotherapy are critical 
regulators of epithelial cancer cell proliferation and survival. We first established that CAFs 
are innately resistant to gemcitabine. Next, we determined that CAF-conditioned media 
supported epithelial cell growth and survival during gemcitabine treatment. More 
importantly, we demonstrate that gemcitabine-treated CAFs prolifically secrete exosomes 
that contain chemoresistance-promoting factors like mRNA and microRNA to recipient 
epithelial cells. miR-146a levels were highly increased in CAFs during gemcitabine 
treatment and found within these exosomes, along with mRNA of its upstream transcription 
factor, Snail. PDAC epithelial cells treated with gemcitabine-treated CAF exosomes 
displayed increased levels of Snail mRNA, increased proliferation, and increased 
chemoresistance. Finally, reduction of exosome release suppressed the chemoresistance 
promoting abilities of CAF cells.
Gemcitabine is the standard of care for adjuvant therapy of resectable PDAC and is still one 
of the most commonly used chemotherapeutic agents used in combination therapy. However, 
74% of patients receiving adjuvant gemcitabine eventually relapse (3). Moreover, 
gemcitabine has already proven to be a paradoxical drug as it not only promotes Snail 
expression, but also triggers NFκB activation, CXCR4 expression, induction of reactive 
oxygen species, upregulation of cancer-stem cell markers and AKT activity. Together, these 
undesired side effects lead to increased chemoresistance and cell motility (24–28). We show 
a previously unknown tumor-promoting side effect of gemcitabine treatment. In our study 
we observe that gemcitabine treatment causes CAFs to greatly increase the secretion of 
chemoresistance-promoting exosomes. This evidence suggests that gemcitabine may 
promote chemoresistance through both cell intrinsic and cell extrinsic mechanisms. 
Gemcitabine was previously shown to upregulate expression of the transcription factor Snail 
in PDAC cancer cells (29). Inhibiting Snail suppresses tumor growth, metastasis, and 
chemoresistance in many cancers, including PDAC (29, 30). Our data, showing gemcitabine 
increases Snail expression in pancreatic CAFs, provides new evidence that Snail plays a role 
in mediating chemoresistance in pancreatic cancer fibroblasts in addition to pancreatic 
cancer epithelial cells. Further, our data showing that gemcitabine induces hypersecretion of 
Snail mRNA through exosomes is a previously unknown potential mechanism of cell-
extrinsic chemoresistance.
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Recent studies show oncogenic exosomes can promote invasion (12), deliver oncogenic 
DNA to normal cells (31), increase drug resistance of cancer cells (32, 33), and can prime 
distant organs for metastasis (34–36). Recent data show that that exosomes from cancer-
associated fibroblast play a role in promoting chemoresistance in colorectal and breast 
cancer cells (32, 33). In our study, we show new evidence that gemcitabine treatment of 
cancer-associated fibroblasts causes increased release of chemoresistance promoting 
exosomes. Based on evidence that the tumor bulk in PDAC is comprised mostly of 
fibroblasts (4), it is possible that the role of CAF-derived exosomes may be even more 
important in pancreatic cancer than other cancers. Our data supports the exploration of using 
exosome secretion inhibitors in combination with currently approved therapeutic regimens 
to combat chemoresistance. GW4869 was shown to greatly diminish CAF exosome 
secretion as well as alleviate chemoresistance in co-cultured cancer cells in vitro and 
contributed to suppressed tumor growth in vivo. Further in vivo studies are needed to fully 
explore the potential benefit of using GW4869 to increase efficacy of combination 
treatments. This would include testing GW4869 and various chemotherapy combinations on 
autochthonous PDAC mouse models and monitoring tumor growth and survival.
In conclusion, we show that fibroblasts exposed to chemotherapy play an active role in 
promoting proliferation and chemoresistance of cancer cells through exosome signaling. The 
role of exosomes in PDAC chemoresistance is an area that requires much elucidation. 
Currently available therapeutic regimens may have greater efficacy when treatments 
designed to inhibit exosome secretion are utilized.
MATERIALS AND METHODS
Cell Lines and Cell Culture
Commercial pancreatic cancer epithelial cell lines were purchased from ATCC. Dr. Timothy 
Donahue (University of California, Los Angeles) provided L3.6pl cells (37). Fibroblast cell 
lines were generously gifted by Dr. Melissa Fishel of IU Simon Cancer Research Center. 
Briefly, patient-derived PDAC tumor tissue was minced into 1–3mm fragments, trypsinized 
for 30 minutes, washed in DMEM with 10% FBS, plated in a petri dish with DMEM 
containing 10% FBS, and fibroblasts were allowed to grow out of tumor fragments for 2–3 
weeks. Cells were infected and immortalized with hTERT by the Hanenberg Lab (IUPUI). 
Cells were authenticated by IDEXX RADIL™ and were found to be mycoplasma free and 
did not genetically match any cell line in the DSMZ database. Cells used in experiments 
ranged from passage 2–10. Fibroblast nomenclature was reduced for purposes of simplicity 
with “CAF1” referring to UH1301-63 cells, “CAF2”referring to UH1303-02 cells, and 
“CAF3” referring to UH1303-49 cells. SC00A5 cells are wild-type pancreatic fibroblasts 
purchased from VitroBioPharma. Cells were grown in culture according to standard 
procedures and protocols with DMEM (Sigma) or RPMI (Sigma) supplemented with 10% 
FBS (RMBI) and 1% Pen-Strep (Life Technologies). L3.6 and fibroblast cells were grown in 
DMEM with 10% FBS and 1% Pen-Strep. Cells were tested throughout studies for 
mycoplasma using the MycoAlert™ kit (Lonza).
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Lentivirus Transduction
CD63-GFP labeled fibroblasts were created using the pCT-CD63-GFP (pCMV, Exosome/
Secretory, CD63 Tetraspanin Tag, plasmid DNA) HIV lentiviral vector purchased from 
System Biosciences. Briefly, 50,000 cells were plated per well of a 6-well plate and 
lentivirus was added 24 hours later utilizing an MOI of 20. Cells were left undisturbed for 
48 hours then moved to a flask and treated with puromycin (1:1000) until all remaining cells 
were fluorescent and thereafter cultured normally.
Exosome Collection, Detection, and Quantification
Collection—Cells were grown in exosome-free media. Media from cells was collected, 
cells were washed with 3ml PBS, and PBS was collected. Media and PBS together was spun 
down at 1,200 RPM for 5 minutes, supernatant was spun down at 16,500× g for 20 minutes, 
and exosomes in supernatant were isolated with the ExoQuick-TC™ system according to 
System Bioscience’s protocol: https://www.systembio.com/downloads/
Manual_ExoTC_WEB.pdf. Exosome pellets were resuspended PBS.
Transmission Electron Microscopy—Exosomal protein was measured via a BCA 
assay, and 10µg exosomes were placed on copper grid. Exosomes were wicked off to create 
a thin layer prior to addition of a thin layer of 2% uranyl acetate in water. Grids were 
allowed to dry overnight, and TEM performed the next day
Particle Size Analysis—Exosomes were resuspended in PBS and particle sizes were 
measured using the Beckman Coulture® Delsa™ Nano S Particle Analyzer which uses the 
Brownian motion of particles and dynamic light scattering to measure particle diameters.
Western Blot—Exosomes were isolated with ExoQuick-TC™ from 20ml of cell-
conditioned media and protein blotting was performed according to the manufacture’s 
protocol and standard procedures: https://www.systembio.com/downloads/
Manual_ExoTC_WEB.pdf.
Quantification—Exosomes were quantified using light transmission spectroscopy, as 
previously described (38) measuring number of particles 30–150nm in diameter. For relative 
quantification exosome pellets were resuspended in 200µl PBS and incubated with 10µM 
CFSE at 37°C for 2 hours. Relative fluorescent units were measured via the Molecular 
Devices SpectraMax® M3 Multi-Mode Microplate Reader. Total corrected cell fluorescence 
used to quantify CD63-GFP labeled cells was obtained using ImageJ, wherein corrected 
total cell fluorescence=integrated density-(area of fluorescent cells × mean of background 
fluorescence)
In Vitro Exosome Transfer, Media Transfer, and Co-culture
Exosome Treatment—Cells were plated at 500,000 cells/flask in exosome-free media 
and were either treated with 1µM gemcitabine or PBS for 4 days. Exosome pellets were 
collected with ExoQuickTC (see protocol link above) and resuspended in 400µl PBS. 
Recipient cells were plated in 6-well plates and treated with new media and10µl exosomes 
per day for 6 days.
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Media Transfer—Both donor and recipient cells were plated at 60,000 cells per well in 6 
well plates, the donor media was spun down at 1,200 RPM for 5 minutes, and the 
supernatant was transferred to recipient cells each day for 6 days. Cells were then treated 
with gemcitabine or PBS for 3 days prior to cell quantification. In studies with AsPC1 cells, 
CAFs and AsPC1 cells were plated at one million cells cells/flask in exosome free media 
and conditioned media was collected and spun down at either 16,500× g for 20 minutes or 
16,500× g for 20 minutes as well as 120,000× g for 70 minutes to deplete the media of 
exosomes without depletion of proteins. Cells were grown in conditioned media for four 
days, treating with new conditioned media each day, then treated with 1µM gemcitabine for 
three days while in conditioned media prior to quantification of live cells.
Co-culture—Cells were plated in a 12-well plate and on 12-well Transwell® polyester 
permeable supports (Corning) with 0.4µm pore size. Cells were co-cultured for 3–6 days 
while cells on the permeable support were treated with GW4869 (20µM) or DMSO, and 
then cells below the support were treated with gemcitabine (100nM–1µM) for 3 days prior to 
quantification of live cells. The number of cells plated per well and concentration of 
gemcitabine used was dependent upon the previously determined chemosensitivity of the 
cell lines (39) and cell proliferation rate. Cells on permeable supports were treated with 
20µM GW4869 or DMSO once every 3 days. Permeable supports of the control group 
received either media alone or media + GW4869. Epithelial cells treated with CD63-GFP-
labelled CAF-conditioned media were incubated in new conditioned media each day for two 
days prior to washing the cells and imaging. CD63-GFP CAFs were grown in phenol red 
free media for 24 hours, media was spun at 16,500× g for 20 minutes, and supernatant was 
placed onto recipient cells.
RT-PCR and RNA Collection
RNA was collected using TRIzol® according to standard protocol: https://
tools.thermofisher.com/content/sfs/manuals/trizol_reagent.pdf. RT-PCR was performed 
according to the QIAGEN provided protocol. QIAGEN SYBR® Green QuantiFast RT-PCR 
kit and protocol was utilized for quantification of mRNA, and QIAGEN miScript II RT Kit 
and protocol along with QIAGEN miScript SYBR® Green PCR Kit and protocol was 
utilized for quantification of miRNA with the Bio-Rad CFX Connect™ Real-Time PCR 
Detection System. miRNA and mRNA primer assays from QIAGEN were utilized. mRNA 
was normalized to GAPDH and miRNA was normalized to RNU6. Exosomal RNA was 
collected with the ExoQuick-TC™ reagent and TRIzol® RNA isolation method. Exosome 
pellets were incubated in TRIzol® for 1–2 hours prior to the isolation procedure. See 
exosome and RNA collection methods above.
Western Blot
Protocol was carried out as previously described (40). E-cadherin antibody was used at 
1:1000 dilution and HRP-conjugated secondary used at 1:3000. See supplementary table S2 
for antibodies used.
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Statistical Analyses
Five biological replicated were utilized in MTT assays. Six biological replicates were used 
in mouse studies. All other studies utilized three biological replicates. RT-PCR experiments 
also utilized three technical replicates. Sample sizes were determined to ensure adequate 
power to detect a pre-specified effect size when applicable based on previously generated 
data. Data are presented as the mean ± standard deviation. Statistical significance was 
calculated via Microsoft Excel using a Student t test (one-sided) or ANOVA as appropriate. 
Data generated displayed normal distribution with similar variances, and analysis was 
performed assuming equal variances. * Denotes p-value<0.05 **denotes p-value<0.01
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Pancreatic fibroblasts are innately chemoresistant. (a) Immunofluorescence stain for αSMA 
and vimentin of cancer-associated fibroblasts (CAF1) and wild-type (WT) fibroblasts. (b) 
Cells were treated with 1µM gemcitabine for 2–6 days and live and dead cells were counted 
to obtain percent cell survival. (c) Cells were treated with 1µM gemcitabine for 2 days or left 
untreated and total cells were counted to obtain percentage of proliferation retention during 
GEM treatment. (d) Percent cell survival of CAFs (CAF2) and epithelial cells (PANC1) with 
similar proliferation retention rate over 6 days 1µM gemcitabine treatment. **p-value<0.01
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Figure 2. 
Pancreatic CAF1-conditioned media increases proliferation and survival of epithelial cells. 
(a) L3.6 cells were grown in CAF1-conditioned media or L3.6-conditioned media for 8 days 
and total cells were counted. (b) Cell proliferation assay (MTT assay) was performed after 8 
days L3.6 cell growth in conditioned media. (c) L3.6 cells were grown in cell-conditioned 
media for 6 days then treated with 100nM gemcitabine for 3 days, and live cells were 
counted. (d) Cell proliferation assay (MTT) was performed after 6 days L3.6 cell growth in 
conditioned media and 3 days of 100nM gemcitabine treatment. **p-value<0.01
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Figure 3. 
Gemcitabine increases CAF exosome secretion. (a) CAF1s were left untreated (NT) or 
treated with 1µM gem (GT) for 4 days. Exosomes were isolated from conditioned cell 
media, and protein lysates were used to perform a western blot for CD81 and beta-actin 
(left). Isolated exosomes were examined for size and structure via transmission electron 
microscopy (right). (b) CAF1 cells transduced with a GFP-CD63 lentivirus (GFP-CD63-
CAF1s) were treated with 1uM gemcitabine (GT) or left untreated (NT) and fluorescence 
was analyzed via microscopy. (c) Total corrected cell fluorescence of GFP-CD63-CAF1 
cells was quantified using ImageJ. (d) Cells were treated with 1µM gemcitabine (Fibroblasts 
and PANC1), 10nM gemcitabine (L3.6), or left untreated for 4 days (NT), and exosomes 
were collected and quantified. Scale bar, 200 µm. *p-value<0.05; **p-value<0.01
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Figure 4. 
GT-CAF exosomes increase cell number and survival of epithelial cells. (a) L3.6 cells were 
treated with GFP-CD63-CAF1 conditioned media for 48 hours and exosome uptake was 
visualized. (b) L3.6 cells were treated with L3.6, GT-PANC1, or GT-CAF1 exosomes for 6 
days and total cells were counted. (c) L3.6 cells were treated with L3.6, GT-PANC1 or GT-
CAF1 exosomes for 6 days and 1µM GEM for 3 days, and live cells were counted. (d) 
PANC1 cells were treated with PANC1 or GT-CAF1 exosomes for 6 days. AsPC1 cells were 
treated with AsPC1 or GT-CAF1 exosomes for 6 days. Total cells were counted. (e) PANC1 
cells were treated with PANC1 or GT-CAF1 exosomes for 6 days, and AsPC1 cells were 
treated with AsPC1 or GT-CAF1 exosomes for 6 days. All cells were then treated with 1µM 
GEM for 3 days, and live cells were counted. *p-value<0.05; **p-value<0.01
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Figure 5. 
Pancreatic fibroblasts upregulate and secrete miR-146a and Snail during gemcitabine 
treatment. (a) RT-PCR. miR-146a and Snail levels were altered in CAF1s during 1 µM GEM 
treatment (GT) (3 days) compared to untreated control (NT). (b) RT-PCR. CAF1s were 
treated with Snail-siRNA, and Snail and miR-146a expression was measured compared to 
negative siRNA control treated CAFs. (c) Exosomes from untreated and 1µM GEM-treated 
CAF1s were isolated and Snail mRNA and miR-146a within CAF1 exosomes was quantified 
via RT-PCR using relative Ct values. (d–e) L3.6 cells were treated with GT-CAF1 exosomes 
for 6 days (GT-CAF1/L3.6) or left untreated (L3.6 control). AsPC1 cells were treated with 
GT-CAF1 exosomes for 6 days (GT-CAF1/AsPC1) or left untreated (AsPC1 control). Snail 
(d) and miR-146a (e) levels were quantified in recipient cells via RT-PCR. *p-value<0.05; 
**p-value<0.01
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Figure 6. 
Inhibition of CAF exosome signaling suppresses chemoresistance. (a) AsPC1 cells were 
grown for 5 days in AsPC1-conditioned media (AsPC1/AsPC1), CAF1-conditioned media 
(CAF1/AsPC1) or CAF1-conditioned media depleted of exosomes (CAF1-ED/AsPC1) and 
then treated with 1µM GEM for 3 days and live cells were counted. (b) CAF1s were treated 
with 20µm GW4869 or DMSO along with 1µM gemcitabine or PBS for 3 days. Exosomes 
in media were collected, dyed with CFSE, and quantified. (c) AsPC1 cells were co-cultured 
with AsPC1 cells, CAFs, GW4869-treated CAF1s, DMEM alone (Blank/AsPC1), or 
GW4869 in DMEM (Blank+GW4869) for 6 days then treated during co-culture with 1µM 
gemcitabine for 3 days. Live co-cultured AsPC1 cells at the bottom of the plate were 
counted. (d) Snail expression was measured via RT-PCR in AsPC1 cells co-cultured with 
untreated CAFs (CAF-NT/AsPC1) or GW4869-treated CAFs (CAF-GW/AsPC1). (e) L3.6 
cells were cultured in CAF1-conditioned (CAF1/L3.6) media or CAF1-conditioned media 
depleted of exosomes (CAF1-ED/L3.6). miR-146a expression was measured via RT-PCR. 
**p-value<0.01
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Figure 7. 
Schematic overview of CAF exosome signaling during gemcitabine treatment. Gemcitabine 
treatment leads to upregulation of Snail and miR-146a as well as exosome secretion in CAFs 
that could lead to increased cell proliferation, tumor growth, and chemoresistance of 
adjacent cancer epithelial cells. GW4869 suppresses exosome release and therefore 
exosomal transfer of Snail and miR-146a.
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